Comparative Pharmacology
Head-to-head clinical analysis: CANDESARTAN CILEXETIL HYDROCHLOROTHIAZIDE versus METAHYDRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANDESARTAN CILEXETIL HYDROCHLOROTHIAZIDE versus METAHYDRIN.
CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE vs METAHYDRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Candesartan cilexetil is a prodrug that is hydrolyzed to candesartan, an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor, inhibiting vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption.
Metahydrin (trichlormethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing excretion of water, sodium, chloride, and potassium.
Initial dose: 1 tablet (candesartan cilexetil 16 mg / hydrochlorothiazide 12.5 mg) orally once daily; titrate based on response to maximum dose of 32 mg/25 mg once daily.
Oral, 50-100 mg once daily. Maximum 200 mg/day.
None Documented
None Documented
Candesartan: ~9 hours (terminal); Hydrochlorothiazide: 6–15 hours (terminal). Both support once-daily dosing.
18-30 hours (clinically relevant for once-daily dosing in hypertension; prolonged in renal impairment)
Candesartan: 33% renal, 67% biliary/fecal. Hydrochlorothiazide: ≥95% renal (unchanged).
Renal: 30% (fecal: 70% as unabsorbed drug, primarily biliary elimination; <1% unchanged in urine)
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic